Part 1 (S1): FOLFOX + Bevacizumab + Durvalumab + Oleclumab for Colorectal Cancer

"Participants of this medical study must be 18 years or older, and under 101."

"Currently, 1135 studies centred on Experimental are active. Of these trials, 301 have reached the Phase 3 stage. The majority of these medical experiments have been conducted in Guangzhou, Guangdong; however, there exist 48 862 sites running trials for this treatment."

"At present, there are 16 clinical sites running this trial. These include Edmonton, Philadelphia and Sacramento in addition to other cities. To minimize any travel burden that may be associated with enrolling, participants should consider selecting the closest clinic to them."

"This study is no longer obtaining participants. The trial was first posted on September 13th 2019 and the most recent update occurred in October 31st 2022. If you are interested in other research, 856 clinical trials are actively recruiting patients with colorectal carcinoma while 1135 studies remain open for Experimental drug testing enrolment."

"This clinical trial has opened their recruitment for 61 patients between 18 and 101 years of age, suffering from colorectal carcinoma. In addition to the requirements based on age, applicants must have adequate organ function, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, a documented mutation test during screening with confirmed tumor locations from disease assessment, no defective DNA mismatch repair (MSI), not received any prior systemic therapy within 6 months of completing adjuvant regimen., at least one lesion that is measurable by RECIST v1.1 and if they are taking anticoagulant medication it must"

"Experimental is frequently used to treat locally advanced cases of nonsquamous non-small cell lung cancer and can also be prescribed for metastatic colorectal cancer, advanced gastric cancer, and other non-immunocompromised conditions."

"The main purpose of this investigation is to measure the antitumor activity of FOLFOX plus bevacizumab plus novel oncology therapy combinations versus FOLFOX plus bevacizumab through a 28 day period in part 1, and an OR rate as recorded during part 2. Safety will also be monitored by assessing clinically significant laboratory values. Additional secondary objectives include measuring efficacy with DCR (defined as confirmed CR, confirmed PR or SD) based on RECIST v1.1, as well evaluating DoR (the duration from first documentation of response until progression or death due to any cause)."

"This particular trial is not accepting participants at the moment. It was initially listed on September 13th 2019 and last updated October 31st 2022, so it may open up again in due time. There are 856 studies which seek enrolment from colorectal carcinoma patients and 1135 experiments that require volunteers now."